RxDoctor Payments Data

Chastity Stephens, APRN

Psychiatric/Mental Health · Fort Smith, ARNPI 1588299291

Payments from drug & device makers

$1,298in general payments, 2019–2025

Across 20 payments — averaging $64.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$213
  • Neurocrine Biosciences, Inc.$211
  • AbbVie$195
  • Axsome Therapeutics, Inc.$187
  • Otsuka America Pharmaceutical, Inc.$138
  • E.r. Squibb & Sons, L.L.C.$117
  • plus $237 from 3 others

What the payments were for

  • Food & beverage$1,298100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,298 in reported general payments places this provider in the 60th percentile of 359 psychiatric/mental health providers in Arkansas.

See all psychiatric/mental health providers in Arkansas

Medicare billing

Part B allowed, 2024
$7,314
Medicare patients
35
Services billed
87

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate17$147,583
Invega SustennaPaliperidone Palmitate23$71,089
VraylarCariprazine Hcl19$27,939
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl23$5,244
Oxcarbazepine87$3,966
Aripiprazole110$3,891
Clozapine44$3,713
Hydroxyzine Hcl102$3,059
Paliperidone ErPaliperidone31$2,929
Atomoxetine Hcl28$2,714
Chlorpromazine Hcl14$2,635
Lurasidone Hcl25$2,275
Ziprasidone Hcl34$1,677
Quetiapine Fumarate101$1,632
Duloxetine Hcl73$1,539

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$211$147,58317 claims
Johnson & JohnsonInvega Sustenna$100$71,08923 claims
AbbVieVraylar$195$27,93919 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 359 psychiatric/mental health providers in Arkansas.

Other psychiatric/mental health in Fort Smith

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →